plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU Patients
Studio in Aperto Sulla Somministrazione di Plasma di Paziente Convalescente da COVID- 19 a Paziente Con Polmonite COVID-19 Ospedalizzato, Non in Terapia Intensiva
Lead SponsorAzienda USL Toscana Nord Ovest
Aim of the study is to verify the efficacy and safety of convalescent hyperimmune plasma infusion in hospitalized covid-19 patients non in ITU with pneumonia and respiratory symptoms within seven days from the beginning of symptoms.
Efficacy is evaluated by the number of patients who will improve their clinical condition and will not be admitted to ITU. .Safety is considered in relation to adverse reactions to plasma infusion.
immune covid 19 plasma infusion
Inclusion Criteria: > 18 years hospitalized patients with positive covid-19 swab with respiratory symptoms and CT confirmation of covid-19 chest disease admitted to non ITU recovery area. informed consent for plasma infusion informed consent to blood samples storing for future studies. Exclusion Criteria: pregnant or breastfeeding female patient or planning for a pregnancy in the period of the study immunoglobulin infusion in the last month contraindication to transfusion or previous adverse reaction